AVANT TECHNOLOGIES INC. (AVAI) 8-K Summary

AVAI entered a Joint Venture and License Agreement on Nov 1, 2025, forming Insulinova, Inc. with Singapore-based Austrianova.

• Purpose: Develop and commercialize cell-based products, leveraging Austrianova’s cell encapsulation IP.
• Ownership Structure: 50% AVAI / 50% Austrianova.
• AVAI Commitment: Contribute up to $1.5 million USD in capital and resources over the first 18 months.
• Significance: This establishes a material strategic partnership in the biotech/cell therapy sector.

The filing contains